U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H16N2O2
Molecular Weight 256.2997
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Nafagrel

SMILES

OC(=O)C1=CC2=C(CC(CN3C=CN=C3)CC2)C=C1

InChI

InChIKey=VJJHOPPXRPHVCA-UHFFFAOYSA-N
InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C15H16N2O2
Molecular Weight 256.2997
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
A possible involvement of thromboxane A2 and peptide leukotrienes in hyperresponsiveness of Sephadex-treated rat lung parenchyma.
1999-01
Inhibitory effect of thromboxane A2 synthetase inhibitor, DP-1904, on antigen-induced contraction of human lung parenchyma.
1996-12
The pharmacokinetics and pharmacodynamics of a new thromboxane synthetase inhibitor, 6-(1-imidazolylmethyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (DP-1904) in man after repeated oral doses.
1990-07
Patents

Sample Use Guides

Japanese normal male volunteers received repeated oral doses of 200 mg every 12 h for 4 doses, or 400 mg every 24 h for 2 doses, or 200 mg every 12 h for 14 doses.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: An augmented contraction and elevated thromboxane (TX) B2 release were observed, when the isolated parenchyma from Sephadex-treated rats was stimulated by 5-hydroxytryptamine (5-HT).
In the Sephadex-induced hyperresponsiveness model, Nafagrel at the concentrations of 3 x 10(-7) to approximately 3 x 10(-6) M, reduced the augmented contraction.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:29:16 GMT 2025
Edited
by admin
on Mon Mar 31 18:29:16 GMT 2025
Record UNII
98PDQ9OL4V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SR 96325A
Preferred Name English
Nafagrel
INN  
INN  
Official Name English
nafagrel [INN]
Common Name English
(±)-5,6,7,8-TETRAHYDRO-6-(IMIDAZOL-1-YLMETHYL)-2-NAPHTHOIC ACID
Systematic Name English
SR-96325
Code English
Classification Tree Code System Code
NCI_THESAURUS C1327
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
Code System Code Type Description
PUBCHEM
65851
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
EVMPD
SUB09113MIG
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
CAS
97901-21-8
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
SMS_ID
100000084429
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
INN
6700
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
MESH
C056295
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
NCI_THESAURUS
C76398
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL1189780
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
EPA CompTox
DTXSID70869308
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
FDA UNII
98PDQ9OL4V
Created by admin on Mon Mar 31 18:29:16 GMT 2025 , Edited by admin on Mon Mar 31 18:29:16 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IC50
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY